Merck's Keytruda Qlex offers a groundbreaking subcutaneous cancer treatment, enhancing patient convenience with faster ...

Merck & Co. Inc. (NYSE:MRK) is one of the best value stocks in Goldman Sachs’ portfolio. On September 19, the company ...

The FDA approved the use of pembrolizumab (Keytruda; Merck) and berahyaluronidase alfa-pmph (Keytruda Qlex; Merck) for use in patients 12 years and older with solid tumor indications approved for the ...

The FDA has granted approval to subcutaneous Keytruda for use in adults and pediatric patients with a solid tumor.

Yeztugo (lenacapavir) is an HIV-1 capsid inhibitor that is administered every 6 months after an initial dosing regimen.

With a fresh endorsement from the FDA, Johnson & Johnson has rounded out Tremfya’s presence in inflammatory bowel disease ...

The FDA has approved the biologics license application (BLA) for the subcutaneous (SC) administration of pembrolizumab ...

The latest findings reported by Novartis reinforce Kesimpta’s efficacy in reducing annualised relapse rate (ARR). The ARTIOS ...

Medical experts have warned against a new weight-loss drug - dubbed the Godzilla of fat-jabs - as it appears to be being sold ...

The drug, which is known as the ‘Godzilla’ of slimming jabs, is still going through lengthy clinical trials in the United ...

Merck receives two positive EU CHMP opinions for Keytruda for SC administration and for new indication for earlier-stage head and neck cancer: Rahway, New Jersey Saturday, Septemb ...

Annual Meeting 2025, findings from a Phase II clinical trial of NA-931 were presented. The study evaluated the weight-loss ...